Plasma homocysteine and microvascular and macrovascular complications in type 1 diabetes: A cross-sectional nested case-control study

Journal of Internal Medicine

Volumn 258, Issue 5, 2005, Pages 450-459

  Soedamah Muthu, Sabita S ^a,b   Chaturvedi, N ^c   Teerlink, T ^d   Idzior Walus, B ^e   Fuller, J H ^a   Stehouwer, C D A ^f  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e JAGIELLONIAN UNIVERSITY   (Poland)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Albuminuria; Cardiovascular disease; Homocysteine; Hypertension; Retinopathy; Type 1 diabetes

Indexed keywords

ALBUMIN; HOMOCYSTEINE;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HOSPITALIZATION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PLASMA; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RETINOPATHY; URINARY EXCRETION; URINE LEVEL; VASCULAR DISEASE;

EID: 27544443267     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2005.01560.x     Document Type: Article

References (50)

1. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
2. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158: 862-7.
3. Henry RM, Kostense PJ, Bos G et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62: 1402-7.
4. Becker A, Kostense PJ, Bos G et al. Hyperhomocysteinaemia is associated with coronary events in type 2 diabetes. J Intern Med 2003; 253: 293-300.
5. Hoogeveen EK, Kostense PJ, Jakobs C et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 2000; 101: 1506-11.
6. Stehouwer CD, Gall MA, Hougaard P, Jakobs C, Parving HH. Plasma homocysteine concentration predicts mortality in non-insulin- dependent diabetic patients with and without albuminuria. Kidney Int 1999; 55: 308-14.
7. Kark JD, Selhub J, Boslom A, Adler B, Rosenberg IH. Plasma homocysteine and all-cause mortality in diabetes. Lancet 1999; 353: 1936-7.
8. Hoogeveen HK, Kostense PJ, Jager A et al. Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study. Kidney Int 1998; 54: 203-9.
9. Chico A, Perez A, Cordoba A et al. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetologia 1998; 41: 684-95.
10. Stabler SF, Estacio R, Jeffers BW, Cohen JA, Allen RH, Schrier RW. Total homocysteine is associated with nephropathy in non-insulin- dependent diabetes mellitus. Metabolism 1999; 48: 1096-101.
11. Buysschaert M, Dramais AS, Wallemacq PH, Hermans MP. Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 2000; 23: 1816-22.
12. Hoogeveen HK, Kostense PJ, Eysink PH et al. Hyperhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus: the Hoorn Study. Arch Intern Med 2000; 160: 2984-90.
13. Looker HC, Hagot-Campagna A, Gunter EW et al. Homocysteine as a risk factor for nephropathy and retinopathy in type 2 diabetes. Diabetologia 2003; 46: 766-72.
14. Jager A, van Hinsbergh VW, Kostense PJ et al. C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler Thromb Vasc Biol 2002; 22: 593-8.
15. Goldstein M, Heibovitch I, Yeffimov I, Gavendo S, Sela B-A, Hoewenstein A. Hyperhomocysteinemia in patients with diabetes mellitus with and without diabetic retinopathy. Eye 2004; 18: 460-5.
16. Hofmann MA, Kohl B, Zumbach MS et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM (corrected and republished article originally printed in Diabetes Care 1997; 20: 1880-6). Diabetes Cure 1998; 21: 841-8.
17. Hultberg B, Agardh K, Andersson A et al. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 1991; 51: 277-82.
18. Vaccaro O, Perna AF, Mancini HP et al. Plasma homocysteine and microvascular complications in type 1 diabetes. Nutr Metab Cardiovasc Dis 2000; 10: 297-304.
19. Agardh E, Hultberg B, Agardh CD. Severe retinopathy in type 1 diabetic patients is not related to the level of plasma homocysteine. Scand J Clin Lab Invest 2000; 60: 169-74.
20. Saeed BO, Nixon SJ, White AJ, Summerfield GP, Skillen AW, Weaver JU. Fasting homocysteine levels in adults with type 1 diabetes and retinopathy. Clin Chim Acta 2004; 341: 27-32.
21. Neugebauer S, Tarnow L, Stehouwer C et al. Total plasma homocysteine is associated with hypertension in type I diabetic patients. Diabetologia 2002; 45: 1315-24.
22. Buysschaert M, Jamart J, Dramais AS, Wallemacq P, Hermans MP. Micro- and macrovascular complications and hyperhomocysteinaemia in type 1 diabetic patients. Diabetes Metab 2001; 27: 655-9.
23. Wollesen F, Brattstrom L, Refsum H, Ueland PM, Berglund L, Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 1999; 55: 1028-35.
24. Veldman BAJ, Vervoort G, Blom H, Smits P. Reduced plasma total homocysteine concentrations in type 1 diabetes mellitus is determined by increased renal clearance. Diabet Med 2005; 22: 301-5.
25. Chen YF, Li PL, Zou AP. Effect of hyperhomocysteinemia on plasma or tissue adenosine levels and renal function. Circulation 2002; 106: 1275-81.
26. Fischer PA, Dominguez GN, Cuniberti LA et al. Hyperhomocysteinemia induces renal hemodynamic dysfunction: is nitric oxide involved? J Am Soc Nephrol 2003; 14: 653-60.
27. Nygard O, Vollset SE, Refsum H et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274: 1526-33.
28. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997; 96: 1745-9.
29. Chaturvedi X, Sjoelie AK, Porta M et al. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes: the EURODLAB PCS. Diabetes Care 2001; 24: 284-9.
30. Koivisto VA, Stevens LK, Mattock M et al. Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. Diabetes Care 1996; 19: 689-97.
31. Chaturvedi N, Fuller JH, Taskinen MR. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. Diabetes Care 2001; 24: 2071-7.
32. Chaturvedi N, Schalkwijk CG, Abrahamian H, Fuller JH, Stehouwer CD. Circulating and urinary transforming growth factor beta1. Amadori albumin, and complications of type 1 diabetes: the EHRODIAB Prospective Complications Study. Diabetes Care 2002; 25: 2320-7.
33. Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Fbeling P, Fuller JH et al. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 2003; 26: 2165-73.
34. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982; 28: 2077-80.
35. Sugiuchi H, Uji Y, Okabe H et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-moditted enzymes and sulfated alpha-cyclodextrin. Clin Chem 1995; 41: 717-23.
36. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
37. Shipehandler MT, Moore EG. Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott IMx analyzer. Clin Chem 1995; 41: 991-4.
38. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 2001; 60: 219-27.
39. Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK. Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM Complications Study. Diabetologia 1995; 38: 437-44.
40. Kearney EM, Mount JN, Watts GF, Slavin BM, Kind PR. Simple immunoturbidimetric method for determining urinary albumin at low concentrations using Cobas-Bio centrifugal analyser. J Clin Pathol 1987; 40: 465-8.
41. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
42. Prineas RJ, Crow RS, Blackburn H. The Minnesota Code Manual of Electrocardiographs Findings. Littleton, Massachusetts 01460, USA: John Wright, 1982.
43. Gonzales-Clemente J-M, Deulofeu R, Mitjavila J et al. Plasma homocysteine is not increased in microalbuminuric patients with type 2 diabetes without clinical cardiovascular disease. Diabetes Care 2002; 25: 632-3.
44. Davies L, Wilmshurst EG, McElduff A, Gunton J, Clifton-Bligh P, Fulcher GR. The relationship among homocysteine, creatinine clearance, and albuminuria in patients with type 2 diabetes. Diabetes Care 2001; 24: 1805-9.
45. Smulders YM, Rakic M, Slaats EH et al. Easting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy. albuminuria, and cardiovascular disease. Diabetes Care 1999; 22: 125-32.
46. van Dijk RA, Rauwerda JA, Steyn M, Twisk JW, Stehouwer CD. Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol 2001; 21: 2072-9.
47. Mangoni AA, Sherwood RA, Swift CG, Jackson SH. Folic acid enhances endothelial function and reduces blood pressure in smokers: a randomized controlled trial. J Intern Med 2002; 252: 497-503.
48. Cook JW, Taylor LM, Orloff SL, Landry GJ, Moneta GL, Porter JM. Homocysteine and arterial disease. Experimental mechanisms. Vascul Pharmacol 2002; 38: 293-300.
49. Audelin MC, Genest J Jr. Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis 2001; 159: 497-511.
50. Shukla N, Thompson CS, Angelini GD, Mikhailidis DP, Jeremy JY. Homocysteine enhances impairment of endothelium-dependent relaxation and guanosine cyclic monophosphate formation in aortae from diabetic rabbits. Diabetologia 2002; 45: 1325-31.